Genentech: AMETRINE-2 - ULCERATIVE COLITIS Fundor: F. Hoffmann-La Roche Ltd
A clinical research study testing Afimkibart, a new anti-inflammatory treatment for Ulcerative Colitis, with all study-related care provided at no cost.
Purpose: This is a randomized trial to evaluate the efficacy and safety of a new type of medication in Ulcerative Colitis. This medication (Afimkibart) is an anti-TL1A inhibitor which decreases both fibrosis and inflammation for patients with IBD. The medication is given through an IV every 2 weeks for the first 12 weeks, and then an injection every 2 weeks following. The study lasts 2 years and participants are then able to get drug at no additional cost for an extended period. In early trials, this drug has shown great efficacy for patients who have Crohn’s Disease and Ulcerative Colitis. All costs (study meds, lab work, procedures) are covered by the sponsor. Patients will be compensated for time and travel.
Qualifications: - You are 18 to 80 years old - Have a confirmed diagnosis of Ulcerative Colitis - Have not had removal of your colon or a current ostomy - Have tried and failed at least 1 prior treatment for your Ulcerative Colitis
Genentech: SIBERITE-2 -- CROHN'S DISEASE Fundor: F. Hoffmann-La Roche Ltd
A randomized clinical trial evaluating the safety and effectiveness of Afimkibart, a novel anti-TL1A therapy, in adults with Crohn’s Disease at no cost.
Purpose: This is a randomized trial to evaluate the efficacy and safety of a new type of medication in Crohn’s Disease. This medication (Afimkibart) is an anti-TL1A inhibitor which decreases both fibrosis and inflammation for patients with IBD. The medication is given through an IV every 2 weeks for the first 12 weeks, and then an injection every 2 weeks following. The study lasts 2 years and participants are then able to get the drug at no additional cost for an extended period. In early trials, this drug has shown great efficacy for patients who have Crohn’s Disease and Ulcerative Colitis. All costs (study meds, lab work, procedures) are covered by the sponsor. Patients will be compensated for time and travel.
Qualifications: - You are 18 to 80 years old - Have a confirmed diagnosis of Crohn’s Disease - Have not had removal of your colon or a current ostomy - Have tried and failed at least 1 prior treatment for your Crohn’s Disease